tradingkey.logo

CVRx Inc

CVRX
6.550USD
-0.090-1.36%
Close 02/06, 16:00ETQuotes delayed by 15 min
171.57MMarket Cap
LossP/E TTM

CVRx Inc

6.550
-0.090-1.36%

More Details of CVRx Inc Company

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

CVRx Inc Info

Ticker SymbolCVRX
Company nameCVRx Inc
IPO dateJun 30, 2021
CEOHykes (Kevin)
Number of employees206
Security typeOrdinary Share
Fiscal year-endJun 30
Address9201 West Broadway Avenue
CityMINNEAPOLIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code55445
Phone17634162850
Websitehttps://www.cvrx.com/
Ticker SymbolCVRX
IPO dateJun 30, 2021
CEOHykes (Kevin)

Company Executives of CVRx Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+5000.00%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+16000.00%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
16.60K
+16600.00%
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-22000.00%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--
Dr. Mudit K. Jain, Ph.D.
Dr. Mudit K. Jain, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kirk Nielsen
Mr. Kirk Nielsen
Independent Director
Independent Director
--
--
Dr. Philip B. Adamson
Dr. Philip B. Adamson
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert John
Mr. Robert John
Chief Revenue Officer
Chief Revenue Officer
--
-55000.00%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+5000.00%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+16000.00%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
16.60K
+16600.00%
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-22000.00%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
US
13.49M
91.85%
Others
1.20M
8.15%
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Johnson & Johnson Innovation-JJDC, Inc.
15.36%
New Enterprise Associates (NEA)
7.73%
Vensana Capital Management LLC
6.53%
Gilde Equity Management Benelux B.V.
4.69%
The Vanguard Group, Inc.
4.28%
Other
61.42%
Shareholders
Shareholders
Proportion
Johnson & Johnson Innovation-JJDC, Inc.
15.36%
New Enterprise Associates (NEA)
7.73%
Vensana Capital Management LLC
6.53%
Gilde Equity Management Benelux B.V.
4.69%
The Vanguard Group, Inc.
4.28%
Other
61.42%
Shareholder Types
Shareholders
Proportion
Venture Capital
29.62%
Investment Advisor
10.99%
Hedge Fund
9.14%
Investment Advisor/Hedge Fund
5.96%
Private Equity
4.69%
Individual Investor
4.32%
Research Firm
3.62%
Pension Fund
0.42%
Bank and Trust
0.14%
Other
31.09%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
228
17.05M
80.90%
-52.59K
2025Q3
232
17.10M
82.20%
-620.32K
2025Q2
227
17.72M
82.14%
-1.50M
2025Q1
219
19.22M
81.40%
-1.99M
2024Q4
217
18.52M
88.19%
+738.46K
2024Q3
205
17.48M
85.56%
+1.01M
2024Q2
202
16.95M
94.67%
-325.79K
2024Q1
200
17.25M
89.54%
-2.08M
2023Q4
194
16.01M
92.75%
+1.64M
2023Q3
187
14.37M
98.58%
+302.86K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Johnson & Johnson Innovation-JJDC, Inc.
4.04M
15.42%
-61.57K
-1.50%
Nov 26, 2025
New Enterprise Associates (NEA)
2.03M
7.73%
--
--
Sep 30, 2025
Vensana Capital Management LLC
1.71M
6.53%
--
--
Dec 31, 2024
Gilde Equity Management Benelux B.V.
1.23M
4.69%
-136.72K
-10.01%
Feb 04, 2025
The Vanguard Group, Inc.
1.09M
4.16%
+12.95K
+1.20%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
939.45K
3.58%
-9.60K
-1.01%
Sep 30, 2025
Jain (Mudit Kumar)
938.43K
3.58%
+1.65K
+0.18%
May 13, 2025
Balyasny Asset Management LP
696.26K
2.66%
+21.57K
+3.20%
Sep 30, 2025
Parkman Healthcare Partners LLC
491.41K
1.87%
-297.69K
-37.73%
Sep 30, 2025
Morgan Stanley & Co. LLC
406.22K
1.55%
+58.56K
+16.84%
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
JPMorgan Fundamental Data Science Small Core ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI